Starting Mounjaro at 2.5mg: what to expect in the first four weeks of weight loss

You've just started your first pen, and the scales haven't moved much

It is a common experience: the pen arrives in a plain DPD box, you take your first injection, and by week three you are wondering whether you are on a real medicine or a very convincing placebo. If you want to understand what to expect at this stage, our guide to Mounjaro 2.5mg and weight loss explains why the starting dose was not designed to produce dramatic results on its own. Its function in the licensed titration schedule is to introduce tirzepatide to your system at a level most people can tolerate, before the prescriber decides whether to step you up.

Tirzepatide works by activating two separate gut-hormone receptors, GIP and GLP-1, both of which influence appetite, the speed at which food moves through your stomach, and the signals your brain receives about fullness. At 2.5mg, those mechanisms are beginning to engage, but the hormonal effect is still modest. Some people notice a meaningful drop in hunger at this stage; others feel almost nothing different. Both responses are normal. What is not normal, and worth telling your prescriber about, is persistent nausea or vomiting that is stopping you eating or drinking adequately, that is a signal that the pace of things may need discussing.

The NHS medicines page for tirzepatide sets out the common side effects clearly. Gastrointestinal symptoms (nausea, a feeling of fullness, looser stools) are most likely to appear in the first days after each injection and usually settle within a week or two as your body adapts.

What the 2.5mg dose means within the wider Mounjaro weight-loss picture

The SURMOUNT-1 trial, which involved more than 2,500 adults with obesity, found that people taking tirzepatide at the highest doses lost an average of around 20 to 21 percent of their body weight over 72 weeks. Those results were not achieved at 2.5mg; they reflect the therapeutic doses reached after months of careful titration. Framing those figures at the starting dose misrepresents what the medicine actually does in a clinical setting.

The licensed UK strengths run 2.5, 5, 7.5, 10, 12.5, and 15mg. A prescriber will typically review progress roughly every four weeks and decide whether it is appropriate to step up. There is no single schedule that fits everyone, factors like tolerability, weight response, and any other health conditions all feed into that decision. You can read a fuller picture of what changes when the dose increases to 5mg once you are ready to think about that stage, and when the time comes to move further, our overview of Mounjaro 7.5mg and weight loss covers what that step typically involves.

NICE's appraisal of tirzepatide, TA1026, provides the framework within which prescribers assess whether treatment is progressing as expected, including a review point if less than five percent of body weight has been lost after six months at the highest tolerated dose.

Side effects to expect at 2.5mg and a few things worth knowing early

Gastrointestinal effects are the most commonly reported at this stage: nausea is the most frequent, followed by reduced appetite, occasional constipation or looser stools, indigestion, and fatigue. Most settle. The clinical advice is to eat smaller portions, avoid rich or fatty foods around injection day, stay well hydrated, and not lie down immediately after eating.

There are a small number of symptoms that always warrant prompt medical attention, regardless of dose. Severe stomach pain that spreads to the back (with or without vomiting) can be a sign of pancreatitis, which the MHRA highlighted in a Drug Safety Update for GLP-1 medicines in January 2026 as an infrequent but potentially serious reaction. Symptoms of a significant allergic response, such as facial swelling or difficulty breathing, also need emergency assessment.

People using oral contraceptives should know that tirzepatide can reduce pill absorption. A non-oral method of contraception (condoms, for example) is recommended for the first four weeks of treatment and for four weeks after each dose increase. NHS England sets this out as part of its weight-management injections guidance.

If you missed an injection or are uncertain about timing, that is a question for your prescriber or the guidance on late doses, not something to navigate by guesswork.

How the first dose fits the private route versus the NHS

On the NHS, tirzepatide is being rolled out in phased cohorts, currently for people with a BMI of 40 or above with four or more qualifying conditions, with further cohorts expanding through 2026 and 2027. For many people that means a wait, or criteria they do not yet meet. Private treatment through a regulated pharmacy is an alternative route, and the 2.5mg starting dose is the same regardless of which route you take.

If you are thinking about starting treatment, our free consultation is reviewed the same day by a GPhC-registered prescriber. No algorithm decides your suitability, a real clinician reads your answers. You can also explore the broader Mounjaro treatment overview if you want to understand the full picture before starting, or read about the range of licensed weight-loss options available. Cost context, if that is a factor, is covered plainly on our Mounjaro cost page.